BioDelivery Sciences International (BioDelivery Sciences International) Risk Assessment

View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of BioDelivery Sciences International is: No Data: Cannot be evaluated.

Competitive Comparison of BioDelivery Sciences International's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioDelivery Sciences International's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Risk Assessment distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Risk Assessment falls into.

BioDelivery Sciences International (NAS:BDSI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

BioDelivery Sciences International Risk Assessment Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612

Website

http://www.bdsi.com

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

Executives

James Vollins	officer: See Remarks	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd	director	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	director	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho	officer: See Remarks	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey	director, officer: Chief Executive Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson	director	324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc	director	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha	officer: See Remarks	1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr	director	BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier	director, officer: Chief Executive Officer	C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith	officer: Chief Medical Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612